Healios K.K. (FRA:6VX)

Germany · Delayed Price · Currency is EUR

1.560

-0.050 (-3.11%)

Last updated: Oct 13, 2026, 8:04 AM CET

Market Cap	224.02M -31.5%
Revenue (ttm)	317.71K -47.3%
Net Income	1.11M
EPS	-0.04
Shares Out	n/a
PE Ratio	200.97
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	68
Open	1.560
Previous Close	1.610
Day's Range	1.560 - 1.560
52-Week Range	1.050 - 2.760
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Nov 12, 2026

About Healios K.K.

Healios K.K., together with its subsidiaries, engages in the research, development, manufacturing, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051, which is preparing for approval for the treatment of acute respiratory distress syndrome; HLCM051, which is preparing for phase 3 clinical trial for the treatment of ischemic stroke; and HLCM051, which is in phase 2 clinical trial for the treatment of trauma, as well as HLCR011, which is in phase 1/2 clinical trial for t... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2011

Employees 75

Stock Exchange Frankfurt Stock Exchange

Ticker Symbol 6VX

Financial Performance

In 2025, Healios K.K.'s revenue was 104.00 million, a decrease of -81.43% compared to the previous year's 560.00 million. Losses were -2.22 billion, -47.65% less than in 2024.

Financial numbers in JPY Financial Statements